Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,581 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urinary Bladder Diseases\Urologic Diseases Clear all
Completed Phase 1 Interventional

Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer

NCT02092948
View directory record Official record
Conditions
Prostate Cancer, Pancreatic Cancer, Bladder Cancer
Interventions
[124I] PSCA-Minibody PET/CT imaging of the whole body
Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 24, 2026, 6:24 AM EDT
Completed No phase listed Observational Results available

Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer

NCT03063125
View directory record Official record
Conditions
Bladder Cancer, Low Testosterone Levels
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 24, 2026, 6:24 AM EDT
Terminated Phase 1 Interventional

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

NCT06336148
View directory record Official record
Conditions
Solid Tumor
Interventions
ACTM-838
Drug
Lead sponsor
Actym Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections

NCT03931408
View directory record Official record
Conditions
Neurogenic Bladder, Spinal Cord Injuries
Interventions
Gentamicin Sulfate, Placebo instillation (saline alone), No instillation
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 24, 2026, 6:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical and Biochemical Evidence of Neurogenic Inflammation in Women With Urinary Urgency

NCT01933074
View directory record Official record
Conditions
Overactive Bladder
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT04454424
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080, Midazolam
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Phase 4 Interventional Results available

Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen

NCT02431897
View directory record Official record
Conditions
Pelvic Organ Prolapse, Urogenital Prolapse, Vaginal Vault Prolapse, Cystocele, Uterine Prolapse, Vaginal Prolapse, Pelvic Floor Disorders
Interventions
Conjugated Estrogens Cream, Placebo Cream
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
48 Years and older · Female only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Birmingham, Alabama • Providence, Rhode Island • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Efficacy Study of Vaginal Mesh for Prolapse

NCT00475540
View directory record Official record
Conditions
Pelvic Organ Prolapse, Uterine Prolapse, Vaginal Prolapse, Cystocele, Rectocele
Interventions
synthetic monofilament polypropylene mesh
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
21 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 24, 2026, 6:24 AM EDT
Recruiting Phase 1Phase 2 Interventional

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT06814496
View directory record Official record
Conditions
Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions
Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy
Drug · Radiation
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Gilbert, Arizona • Tucson, Arizona • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 6:24 AM EDT
Completed No phase listed Observational

Relationship: Interstitial Cystitis & Vulvodynia-Part 2

NCT00751010
View directory record Official record
Conditions
Vulvodynia
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2008 · Synced Oct 24, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

NCT01622660
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine, Pazopanib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Phase 2 Interventional

AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

NCT00003759
View directory record Official record
Conditions
Bladder Cancer
Interventions
BCG vaccine, valrubicin, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Anthra Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 24, 2026, 6:24 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Percutaneous Nerve Evaluation Trial Time

NCT06226220
View directory record Official record
Conditions
Urge Incontinence, Urgency-frequency Syndrome, Overactive Bladder
Interventions
Sacral neuromodulation
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

NCT03558503
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transcutaneous Tibial Nerve Stimulation: the ZIDA Device Equivalence

NCT04470765
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Urinary Incontinence, Urinary Frequency More Than Once at Night
Interventions
Zida
Device
Lead sponsor
Exodus Innovations
Industry
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

NCT02302807
View directory record Official record
Conditions
Bladder Cancer
Interventions
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Docetaxel, Paclitaxel, Vinflunine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
931 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Not applicable Interventional

The Effects of Mindfulness-based Stress Reduction in Interstitial Cystitis Patients

NCT03722992
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
MBSR
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action

NCT01990898
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Cyclosporine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 24, 2026, 6:24 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT03375307
View directory record Official record
Conditions
Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
17
States / cities
Encinitas, California • Irvine, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

NCT00911235
View directory record Official record
Conditions
Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
Interventions
Fesoterodine, fesoterodine plus fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Oct 24, 2026, 6:24 AM EDT
Recruiting Early Phase 1 Interventional

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

NCT04734106
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Desert Harvest Aloe Vera Capsules, Placebo Capsules
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 24, 2026, 6:24 AM EDT
Recruiting Phase 3 Interventional

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284
View directory record Official record
Conditions
High-risk Muscle Invasive Urothelial Carcinoma
Interventions
Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
19
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

NCT05085977
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
TARA-002
Biological
Lead sponsor
Protara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Jacksonville, Florida • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 24, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacterial Genomic Sequencing in Overactive Bladder

NCT01642277
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solifenacin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 24, 2026, 6:24 AM EDT